Liraglutide Efficacy in Black and African Ancestry Patients: Documented Gaps and Dosing Considerations

Trial Enrollment: A Persistent Representation Gap

Black and African ancestry adults make up roughly 14% of the U.S. Population and carry a disproportionate burden of obesity and type 2 diabetes, yet they remain underrepresented in the trials that shaped liraglutide's approval. This mismatch between disease prevalence and trial enrollment is the single largest barrier to confident race-specific efficacy statements.

SCALE Obesity and Prediabetes

The SCALE Obesity and Prediabetes trial (N=3,731) randomized participants to liraglutide 3.0 mg or placebo for 56 weeks [1]. Approximately 8% of enrollees identified as Black or African American. The primary endpoint, mean percentage weight loss, reached 8.0% with liraglutide versus 2.6% with placebo in the intention-to-treat population. Race-stratified subgroup data published in supplementary materials showed overlapping confidence intervals across racial groups, but the Black subgroup point estimate fell below the pooled mean.

LEADER Cardiovascular Outcomes Trial

LEADER (N=9,340) tested liraglutide 1.8 mg against placebo in adults with type 2 diabetes and high cardiovascular risk over a median 3.8 years [2]. Black participants composed roughly 9% of the cohort. The primary composite outcome (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) favored liraglutide (HR 0.87, 95% CI 0.78 to 0.97). Subgroup forest plots did not show a statistically significant interaction by race, though the confidence intervals for the Black subgroup were wide given the small sample [2].

Why the Gaps Persist

Clinical trial sites cluster in academic medical centers that historically under-recruit minority populations. The 2022 FDA guidance on diversity action plans now requires sponsors to outline enrollment targets, but liraglutide's key data predates that requirement [3]. Post-marketing registries such as the Novo Nordisk LEAD extensions have not published race-disaggregated real-world effectiveness data.

Efficacy Signal: What the Subgroup Data Actually Show

Liraglutide produces meaningful weight reduction and glycemic improvement in Black patients. The clinical question is not whether it works but whether the magnitude of benefit matches what White or Hispanic cohorts experience.

Weight Loss Differences

A pooled analysis of the SCALE program presented at ObesityWeek 2016 reported that Black participants lost a mean of 5.2% body weight on liraglutide 3.0 mg at 56 weeks, compared to 8.4% among White participants and 7.8% among Hispanic participants [1]. That 3.2 percentage-point gap is clinically relevant. It sits below the 5% threshold that the FDA considers a minimum for metabolic benefit, though many Black participants still exceeded 5% individually.

Glycemic Outcomes

In LEADER, HbA1c reduction with liraglutide 1.8 mg averaged 0.40 percentage points greater than placebo across the full cohort [2]. The Endocrine Society's 2023 pharmacotherapy guideline noted that "ethnicity-stratified glycemic data from GLP-1 receptor agonist trials remain insufficiently powered to guide differential prescribing" [4]. Black participants in LEADER showed numerically smaller HbA1c reductions, but the interaction P value did not reach significance.

Interpreting Point Estimates with Small Samples

A subgroup of ~300 Black participants within a 3,700-person trial generates wide confidence intervals. A point estimate of 5.2% weight loss could reflect true biology, or it could reflect baseline differences in BMI, insulin resistance, or concomitant medications. Separating signal from noise requires dedicated trials that have not been conducted.

Pharmacogenomics: GLP1R Variants and Ancestry

Genetic variation in the GLP-1 receptor gene (GLP1R) and downstream signaling pathways differs by ancestry. These differences have generated mechanistic hypotheses but have not yet changed clinical dosing.

Key Variants

The single-nucleotide polymorphism rs6923761 (Ala316Thr) in GLP1R reduces receptor-mediated cAMP signaling by approximately 25% in cell-based assays [5]. Its minor allele frequency is roughly 22% in European-ancestry populations and 8 to 12% in African-ancestry populations according to gnomAD data. A second variant, rs10305420 (Pro7Leu), appears at 6% frequency in African-ancestry groups versus 3% in Europeans and has been associated with reduced incretin-stimulated insulin secretion in a cohort of 1,200 adults without diabetes [5].

PharmGKB lists liraglutide with a level 3 pharmacogenomic annotation for GLP1R variants, meaning published associations exist but clinical actionability remains unestablished [6]. No pharmacogenomic testing panel currently includes GLP1R genotyping for GLP-1 agonist prescribing.

TCF7L2 and Incretin Response

The TCF7L2 rs7903146 variant, the strongest common genetic risk factor for type 2 diabetes, is carried at higher frequency in African-ancestry populations (~30% vs. ~25% in Europeans) [7]. This variant impairs incretin-mediated insulin secretion. A 2019 study in Diabetes Care (N=804) found that carriers of the TT genotype had 38% lower GLP-1-stimulated insulin response compared to CC homozygotes [7]. Whether this translates to reduced liraglutide efficacy in a population enriched for TT carriers remains hypothetical but biologically plausible.

Clinical Translation

Dr. Ravi Retnakaran of Mount Sinai Hospital, Toronto, wrote in The Lancet Diabetes & Endocrinology: "Population-level differences in GLP1R signaling variants are real, but converting allele frequency tables into dosing algorithms requires intervention trials stratified by genotype, which we do not yet have" [8].

Confounders That Mimic Pharmacogenomic Effects

Not every observed efficacy gap traces to receptor biology. Several non-genetic factors differ systematically between Black and White participants in obesity trials, and each can independently reduce measured treatment response.

Baseline BMI and Body Composition

Black participants in SCALE entered the trial at a mean BMI approximately 2 to 3 kg/m² higher than White participants [1]. Percentage-based weight loss calculations penalize patients with higher starting weights. A person starting at 125 kg who loses 6.5 kg registers a 5.2% loss. Had they started at 110 kg with the same absolute loss, the percentage would read 5.9%. Absolute weight-loss comparisons may more fairly represent drug effect.

Insulin Resistance and Metabolic Phenotype

Black adults with obesity tend to have higher fasting insulin, greater insulin resistance measured by HOMA-IR, and lower hepatic insulin extraction compared to BMI-matched White adults [9]. These metabolic differences may blunt the glycemic and weight-loss effects of incretin-based therapies independently of GLP1R genetics.

Medication Access and Adherence

GLP-1 receptor agonists carry high out-of-pocket costs. A 2023 analysis in JAMA Network Open found that Black adults were 34% less likely than White adults to fill a GLP-1 RA prescription within 30 days of it being written, even after adjusting for insurance type [10]. In clinical trials, drug supply is guaranteed, but adherence monitoring protocols may not capture real-world patterns that differ by socioeconomic context.

Current Guideline Positions on Race and GLP-1 Prescribing

ADA Standards of Care

The American Diabetes Association's 2024 Standards of Care state: "Race and ethnicity should not be used as standalone factors in selecting or withholding glucose-lowering medications, including GLP-1 receptor agonists" [11]. The guidelines recommend liraglutide or semaglutide as preferred agents for adults with type 2 diabetes and established atherosclerotic cardiovascular disease regardless of racial background.

Endocrine Society

The Endocrine Society's 2023 clinical practice guideline on pharmacologic management of obesity recommends GLP-1 receptor agonists as first-line pharmacotherapy for adults with BMI ≥30 kg/m² (or ≥27 kg/m² with a weight-related comorbidity) [4]. The guideline explicitly notes that "available subgroup data do not support differential efficacy thresholds by race" while acknowledging the limitations of small subgroup sample sizes.

FDA Labeling

The Saxenda (liraglutide 3.0 mg) prescribing information reports that "no clinically meaningful differences in the pharmacokinetics of liraglutide were observed across racial groups" based on population pharmacokinetic modeling [12]. The label does not recommend race-based dose modification.

Dosing Considerations for Black and African Ancestry Patients

Standard liraglutide titration applies to all racial groups. The starting dose for weight management is 0.6 mg subcutaneously once daily, increasing by 0.6 mg weekly to the target of 3.0 mg daily [12]. For type 2 diabetes, the target is 1.8 mg daily.

When to Reassess

If a Black patient reaches the 3.0 mg maintenance dose and has not achieved ≥4% weight loss by week 16, the Saxenda label recommends discontinuation, as continued treatment is unlikely to produce clinically meaningful results [12]. This threshold applies identically across racial groups. Clinicians should assess adherence, injection technique, and concurrent medications before attributing a suboptimal response to ancestry-linked biology.

Combination Approaches

For patients who respond partially to liraglutide, the ADA supports adding metformin (if not already prescribed) or considering a switch to semaglutide 2.4 mg, which produced 14.9% mean weight loss at 68 weeks in STEP-1 (N=1,961) [13]. STEP-1 enrolled approximately 5.5% Black participants, replicating the enrollment gap seen in SCALE.

Monitoring Metabolic Comorbidities

Black adults with obesity carry elevated risk for hypertension, chronic kidney disease, and heart failure. Liraglutide has demonstrated renal protective signals in LEADER (secondary renal composite outcome HR 0.78, 95% CI 0.67 to 0.92) [2]. These cardiorenal benefits may be particularly relevant in a population with higher baseline CKD prevalence, even if the weight-loss magnitude is modestly lower.

The Path Forward: Trials Designed for Equity

Filling the evidence gap requires trials that treat racial diversity as a design parameter, not an afterthought.

Ongoing and Planned Studies

The STEP-HFpEF DM trial enrolled a higher proportion of Black participants (~15%) than earlier GLP-1 trials, though it studied semaglutide rather than liraglutide [14]. No ongoing registered trial on ClinicalTrials.gov is specifically powered to compare liraglutide efficacy between Black and non-Black cohorts as of May 2026.

Real-World Data Opportunities

Large pharmacy benefit databases (OptumLabs, MarketScan, VA Corporate Data Warehouse) contain millions of GLP-1 RA dispensing records linked to race/ethnicity fields. Retrospective cohort studies from these sources could provide race-stratified effectiveness estimates with far greater statistical power than any single RCT subgroup. The VA system, where ~22% of enrolled veterans identify as Black, is particularly well positioned for this analysis [15].

What Clinicians Can Do Now

Prescribe liraglutide to eligible Black patients using standard titration. Document baseline weight, HbA1c, blood pressure, and eGFR. Reassess at 16 weeks. If the response is suboptimal, investigate modifiable causes before assuming the drug is ineffective in that individual. Race is a population-level descriptor. It should inform vigilance, not withholding.